Antimicrobial peptide papers may report a growth threshold, a change in recoverable organisms or an image of altered cells. These endpoints provide different kinds of evidence. The first task is to identify the observation behind the antimicrobial label, while keeping research findings separate from recommendations for treating an infection.
Read MIC as a defined growth endpoint
Kadeřábková and colleagues’ original methods paper describes MIC as the lowest antimicrobial concentration that inhibits visible bacterial growth in the test. It stresses reporting the assessment system and applicable guideline version so that results can be interpreted in context.Kadeřábková and colleagues — Antibiotic susceptibility testing using minimum inhibitory concentration assays (opens in a new tab)
Retain the tested organism and strain. A result for one isolate should not become a statement that every member of its species responds identically.
Read how growth was assessed and what counted as inhibition. A partly reduced signal is a different endpoint from the specified absence of visible growth, unless the method explicitly defines another criterion.
The concentration belongs to the experimental system. Do not convert it into an amount for human use or assume that it describes exposure achievable at a biological site.
When a peptide is called active, locate the criterion supporting that description. The term alone does not reveal the test range, endpoint or degree of uncertainty.
Preserve the limits of the tested range
| Reported result | What it says |
|---|---|
| MIC = 8 | The stated threshold was reached at the reported test level |
| MIC > 32 | The threshold was not reached within a range ending at 32 |
| MIC ≤ 1 | The threshold was already reached at the lowest tested level of 1 |
The numbers are fictional and are not peptide recommendations. The inequality symbols carry information: greater than 32 is not an exact value of 32, and at most 1 is not necessarily an exact value of 1.
Two candidates reported above the same upper limit cannot be ranked from those entries alone. The study has established a shared measurement boundary, not equal underlying activity.
Similarly, an apparent small difference between reported levels should be assessed against the method and repeat results. A concentration series does not provide unlimited numerical resolution.
When building a comparison table, preserve the original units and qualifiers. Converting units can help comparison, but removing inequality signs makes the data less accurate.
Distinguish growth, survival and mechanism
A growth endpoint reports what developed during the observation window. A viable-count measurement concerns organisms recoverable under its counting method. One should not be relabelled as the other without the relevant observations.
For a time-course result, identify the starting reference and subsequent observations. A lower endpoint than an untreated culture is not necessarily the same as a reduction from the starting count.
For example, an exposed culture that remains near its starting count while a reference culture expands supports a different description from an exposed culture whose recoverable count falls below its starting value.
Also keep the microbial state visible. A result from one experimental population should not automatically be extended to another arrangement or growth state that was not tested.
Separate research activity from clinical categories
EUCAST’s official breakpoint page describes a system for interpreting microorganisms against antimicrobial agents approved for treating infectious diseases. This is a separate interpretive framework from obtaining an experimental MIC for a research peptide.EUCAST — Clinical Breakpoint Tables (opens in a new tab)
A researcher-selected activity threshold is not automatically a clinical breakpoint. If a paper uses susceptible or resistant language, identify the applicable definition rather than infer it from the size of the number.
The same caution applies to claims that one compound is better than another. A numerical comparison needs aligned organisms, endpoints and conditions, and clinical usefulness requires evidence beyond that comparison.
A clear summary names the peptide, organism, assay endpoint and reported limit. It distinguishes any additional survival or mechanism evidence and leaves treatment decisions outside the scope of the laboratory result.
Sources and further detail
- Kadeřábková and colleagues — Antibiotic susceptibility testing using minimum inhibitory concentration assays (opens in a new tab)
Original 2024 methods abstract and interpretation introduction read. Short explanation of the endpoint and reporting context; no microbial culture or assay-execution instructions reproduced.
- EUCAST — Clinical Breakpoint Tables (opens in a new tab)
Official scope and current page checked 19 September 2026. No organism-specific breakpoint, dose or treatment recommendation reproduced. Numerical reporting examples are original.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.